CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2018--
Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced it will host a second quarter 2018 investor update conference
call and webcast at 4:30 p.m. on Wednesday, August 8, 2018.
Individuals interested in participating in the call should dial (877)
458-0977 (U.S. and Canada) or (484) 653-6724 (international) using
conference ID number 1398303. To access the webcast, visit the Investors
section of Akebia’s website at www.akebia.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
Beginning the morning of August 9, 2018, the call will be available for
replay via telephone and the archived webcast will be available on
Akebia’s website. To listen to the telephone replay, dial (855) 859-2056
(U.S. and Canada) or (404) 537-3406 (international) using conference ID
number 1398303. The telephone replay will be available for six days
following the call.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. For more information, please visit our website at www.akebia.com,
which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180801005888/en/
Source: Akebia Therapeutics, Inc.
John Garabo, 617-844-6130